Rakovina Therapeutics and Variational AI Advance Brain-Penetrant ATR Program Toward Development Candidate Selection

Source: The Manila times
Published on: 2026-10-22 09:35

kt-5000AI delivers potent and selective ATR inhibition, CNS-oriented properties and preclinical tumour-growth control, advancing a capital-efficient drug discovery program toward candidate selection VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced significant preclinical progress from its kt-5000AI program, a collaboration with Vancouver-based Variational AI Inc. ("Variational AI") focused on the discovery and development of novel, brain-penetrant inhibitors of ataxia telangiectasia and Rad3-related protein kinase (ATR). Rakovina has advanced the program from target specification through lead generation and five cycles of iterative lead optimization in approximately two years, using Varia...

(Please login to view full article)

Third-Party Content Disclaimer

Content displayed on this platform may include news articles, reports, and other materials aggregated from publicly available third-party sources through automated tools. Such content is not created, written, commissioned, or edited by Straits Interactive Pte Ltd or the Data Protection Excellence (DPEX) Network.

While we take reasonable steps to ensure responsible publication, we do not independently verify all third-party information and make no representations as to its accuracy, completeness, or reliability.

The views, findings, and statements expressed in third-party content belong solely to the original source and do not reflect the views of Straits Interactive Pte Ltd or the DPEX Network.

If you believe any content is inaccurate, infringing, or should be removed, please contact us at legal@straitsinteractive.com. We will review the matter and, where appropriate, take action in accordance with our internal policies.

Unlock these benefits
globe

Get access to news, enforcement cases, events, and actionable tips and guides

email

Get regular email updates and offers

job

Job opportunities, mentorship and career guidance

discuss

Exclusive access to Data Protection community - ask questions, network and share knowledge with peers and experts via WhatsApp and Linkedin